2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2204

Early Treatment With Methotrexate Is Associated With Extensive Re-Ordering Of The Neutrophil Transcriptome In Juvenile Idiopathic Arthritis
Abstract Number: 2574

Early Use of Prostacyclin Therapy Improves Transplant-Free Survival in Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension Plus Interstitial Lung Disease
Abstract Number: 2366

Economic Impact Of Adalimumab Treatment In Japanese Patients With Rheumatoid Arthritis: Analysis Of 24 Weeks Data From The Anouveau Study
Abstract Number: 374

Effect Of Age At Menopause In Women With Early Rheumatoid Arthritis
Abstract Number: 706

Effect Of Aminaftone On Raynaud’s Phenomenon Secondary To Systemic Sclerosis: A Double-Blind Prospective, Randomized, Placebo-Controlled Pilot Study
Abstract Number: 2827

Effect Of Biologic Agents On Lipids and Cardiovascular Risk In Rheumatoid Arthritis Patients
Abstract Number: 382

Effect Of Biologic Disease Modifiers On Cardiovascular Risk Of Patients With Rheumatoid Arthritis – 2 Years Prospective Cohort Study
Abstract Number: 318

Effect Of Brodalumab (AMG 827) On Pain and Physical Functioning In Patients With Psoriatic Arthritis
Abstract Number: 1799

Effect Of Certolizumab Pegol Over 48 Weeks In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Abstract Number: 1178

Effect Of Febuxostat On Serum Urate Levels In Gout Subjects With Hyperuricemia and Moderate-To-Severe Renal Impairment: A Randomized Controlled Trial
Abstract Number: 2147

Effect Of Fish Oil On Structural Progression In Knee Osteoarthritis: A Two Year Randomized, Double-Blind Clinical Trial Comparing High Dose With Low Dose
Abstract Number: 2915

Effect Of Menopause On Skin Thickening In Systemic Sclerosis
Abstract Number: 1804

Effect of Mycophenolate On the White Blood Cell Count and the Frequency of Infection in Systemic Lupus Erythematosus
Abstract Number: 931

Effect Of Neutralizing IL-17A and IL-17F Antibodies On Host Resistance To Acute Mycobacterium Tuberculosis Infection In Mice In Comparison With Neutralizing TNF-α Treatment
Abstract Number: 2559

Effect Of NOX4 Overexpression On The Levels Of Micro RNAs Relevant To Systemic Sclerosis Fibrotic Process

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].